Revvity Signals Software unveils unified data platform to accelerate drug discovery
Revvity, Inc. announced that its software and informatics division, Revvity Signals Software, will launch its Signals One, a unified software platform evolved from the Company's existing research portfolio, designed to streamline data management across the entire drug discovery lifecycle.
The Signals One platform addresses the growing complexity of drug modalities research by delivering a complete solution that integrates advanced research capabilities and fosters collaboration in multidisciplinary workflows.
The Signals One offering provides scientists with an all-in-one solution for managing data across the “Design-Make-Test-Decide” R&D lifecycle. The platform incorporates sophisticated data processing workflows that encompass a range of common analytical tasks, including in vitro curve fitting, in vivo data analysis, and group comparisons. The Signals One offering also ensures assay data is standardized and AI-ready, allowing researchers to uncover hidden relationships and insights through advanced AI tools. As part of its strategic direction, Revvity Signals Software plans to add additional AI enhancements to the user experience, including semantic search, summarization assistants, and automated protocol writing, while continuing to safeguard sensitive intellectual property.
The Signals One platform was introduced at the Bio-IT World Conference & Expo, April 2-4, in Boston, Massachusetts.
